Jean-Charles Epinat

Outlook reCAPTCHA YouTube Google Tag Manager Google Font API Nginx Google Analytics Mobile Friendly Linkedin Marketing Solutions AI

gene editing life sciences oncology tcell therapies genome engineering allogeneic offtheshef cart therapies biotechnology: pharmaceutical preparations health care biotechnology research cellectis talen technology car t-cells immunotherapy allogeneic therapies electroporation system pulseagile cancer treatment clinical trials b-cell malignancies graft vs. host disease pipeline products clinical indications gene-edited therapies lyophilization manufacturing patents clinical data preclinical data fda approval safety switch intellectual property biopharmaceuticals cancer immunology transformative therapy clinical research drug development biotechnology immuno-oncology regulatory compliance therapeutic innovations gene therapies biopark stock listing euronext growth biotechnology company scientific presentations global partnerships investors heavily pretreated illness development pipeline research expertise biologic manufacturing healthcare solutions clinical-stage biopharmaceutical next-generation car t-cell immunotherapies allogeneic car t-cells ucarts off-the-shelf therapies pulseagile electroporation b-cell acute lymphoblastic leukemia non-hodgkin lymphoma acute myeloid leukemia scalable manufacturing strategic collaborations astrazeneca innovative therapeutics patient accessibility unmet medical needs gene-edited cell therapies safety mechanisms graft-versus-host disease transformative therapies healthcare providers oncology market clinical development partnerships research collaborations manufacturing facilities global presence corporate governance sustainability diversity & inclusion hospital & health care health wellness & fitness mechanical or industrial engineering environmental services renewables & environment